Sellers, Jessie
Darby, R. Ryan
Farooque, Alma
Claassen, Daniel O.
Article History
First Online: 29 March 2019
Compliance with Ethical Standards
: The study was approved through the Vanderbilt University Medical Center (VUMC) Institutional Review Board.
: No funding was received for the conduct or reporting of this research.
: Jessie Sellers has received research support and personal fees for speaker bureau participation from Teva Neuroscience. Dr. Darby is supported by grants from the Alzheimer’s Association, Brightfocus Foundation, and Vanderbilt Institute for Clinical and Translational Research. Daniel O. Claassen receives research support from the National Institute of Neurological Disorders and Stroke (NINDS), Griffin Foundation, Michael J. Fox Foundation, and Huntington’s Disease Society of America (HDSA), and pharmaceutical grant support from AbbVie, Acadia, Biogen, BMS, Cerecour, Eli Lilly, Lundbeck, Jazz Pharmaceuticals, Teva Neuroscience, Wave Life Sciences, and Vaccinex. He has received personal fees for consulting and advisory board participation from Acadia, Adamas, Lundbeck, Neurocrine, and Teva Neuroscience. Given a potential conflict with Acadia (makers of pimavanserin), he excluded himself from data acquisition and data analysis, but provided direction on project design, and critical review and revision of the manuscript. Alma Farooque has no conflicts of interest to disclose.